NanoAssemblr® Blaze™: Power To Scale

A candidate drug must be shown to be both potent and non-toxic in relevant models. While early screening in murine models is enough to begin a program, the demands for data from larger models will increase.

Traditionally, process development for nanomedicine production at an intermediate scale is a barrier to this work. With NxGen™ technology on the NanoAssemblr^® Blaze™, these important studies can be conducted efficiently with a process that mirrors a clinical scale implementation.